Nous raises €2.3M seed to take Koncentra, its botanical energy ingredient, into the US

Nous, an Italian startup, has raised €2.315 million in a Seed round led by dsm-firmenich Ventures, the corporate venture arm of the global ingredient company dsm-firmenich, with FoodSeed (part of CDP Venture Capital's national accelerator network for agrifood) co-investing. The capital funds clinical validation, supply chain expansion across Europe and Asia, and a planned launch in the United States.

Nous's core product is Koncentra, a functional ingredient derived from botanical sources via a proprietary extraction process. The company positions it as a clinically studied, natural alternative in the energy and functional beverage category — a segment that has seen considerable growth but persistent scepticism around the quality of ingredient efficacy claims.

An ingredient company, not a brand

Nous is building a B2B ingredient business, not a consumer brand. Koncentra is designed to be incorporated into finished products by beverage companies, nutraceutical manufacturers, and supplement brands — making dsm-firmenich Ventures a strategically logical lead investor rather than a purely financial one. dsm-firmenich is one of the world's largest producers of nutritional ingredients and flavours; its venture arm regularly backs ingredient technologies it could eventually commercialise through its existing supply chain relationships.

"Support from investors with deep expertise in ingredients, foodtech and market scale-up gives us the resources to strengthen the scientific position of Koncentra, expand our supply chain, and build the next generation of functional ingredients," CEO Lorenzo Pessini said.

Clinical evidence as the moat

The functional ingredient market is segmented by how seriously ingredient suppliers treat clinical validation. At one end are commodity botanicals sold with limited evidence; at the other are patented compounds with robust randomised controlled trial data. Nous's stated priority — commissioning additional clinical studies — signals an intent to build the latter type of moat. This is more expensive and slower than a simple launch strategy, but it is more defensible if the evidence holds.

The planned US expansion adds regulatory complexity: the FDA's position on botanical claims in food and beverages differs significantly from the European regulatory framework, and the evidence threshold that satisfies a European brand buyer may not be sufficient for a US one. Whether the additional clinical studies are designed with the US market's regulatory requirements in mind will determine how useful they are for that expansion.